US EditionPublished • loading... • Updated
Eilean Therapeutics Advances ZE74-0282, a Highly Selective Inhibitor of Mutated JAK2 V617F, into First-in-Human Clinical Development
Summary by PR Newswire
30 Articles
30 Articles
Bennington Banner+29 Reposted by 29 other sources
Eilean Therapeutics Advances ZE74-0282, a Highly Selective Inhibitor of Mutated JAK2 V617F, into First-in-Human Clinical Development
DOVER, Del., Dec. 17, 2025 /PRNewswire/ -- Eilean Therapeutics announced the advancement of ZE74-0282 into first-in-human clinical development. ZE74-0282 is a novel, highly selective inhibitor of the mutated Janus kinase 2 (JAK2) V617F variant and is being developed as a…
Coverage Details
Total News Sources30
Leaning Left0Leaning Right2Center9Last UpdatedBias Distribution82% Center
Bias Distribution
- 82% of the sources are Center
82% Center
C 82%
R 18%
Factuality
To view factuality data please Upgrade to Premium
